Apellis Pharmaceuticals, Inc. (APLS): restructuring charge — Apellis announces 25% workforce reduction, expects up to $300M cost savings through 2024

Apellis Pharmaceuticals, Inc.

Reduce workforce by ~225 employees (~25% of total); substantially complete in Q3 2023.
Cost savings of up to $300M through 2024, including $70M+ from workforce reduction and up to $230M from external expenses.
Focus on SYFOVRE U.S. launch and preparation for ex-U.S. launches; reduce EMPAVELI expenses.
Prioritize retina and CNS research; deprioritize siRNA with systemic pegcetacoplan, APL-1030, APL-2006.
Expect $9M-$11M cash costs for restructuring; update on cash runway in Q3 2023 earnings.

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

Apellis Pharmaceuticals, Inc. announced a restructuring with charges of approximately $9 million to $11 million affecting corporate restructuring includes SYFOVRE launch, EMPAVELI reduction, R&D prioritization (approximately 225 employees, or approximately 25% of its current workforce).

Type: restructuring
Charge: approximately $9 million to $11 million
Affected area: corporate restructuring includes SYFOVRE launch, EMPAVELI reduction, R&D prioritization
Headcount: approximately 225 employees, or approximately 25% of its current workforce

Exact text from the filing

in workforce will be substantially completed in the third quarter of 2023. As a result of the reduction in workforce, the Company estimates that it will incur approximately $9 million to $11 million in costs, substantially all of which are cash expenditures. These costs are anticipated to be incurred primarily in the second half of 2023. The estimate of costs

View on SEC.gov

Browse all restructurings & charges →

Apellis Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-222977

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.